A Phase 2 interventional study of venglustat GZ/SAR402671 and Placebo in Parkinson's Disease, sponsored by Genzyme, a Sanofi Company. Terminated at 52 sites in 16 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-05-24.
Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,649 studies in Parkinson Disease with a site in United States — 304 open to participants now, 386 under way, 7 of them phase 3. Parkinson Disease · United States.
Among the 1,649 studies in Parkinson Disease with a site in United States, this one is the 121st largest by enrollment of the 1,256 interventional ones that give a count, is one of 73 that started in 2016, is one of 234 in phase 2, and was the 732nd registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →304 of the 1,649 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 45–75
University of Minnesota · Sites in United States
Ages 18+
Hoffmann-La Roche · Sites in United States, China, Ireland and 2 more countries
Ages 40–85
Medical University of South Carolina · Sites in United States
Ages 50–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,649 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 226 · Phase 2 304 · Phase 3 145 · Phase 4 75
First in 1991; this study’s year is marked. 73 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 273 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 36 across the 1,256 interventional studies, 78 across the 379 observational. Of the 1,140 that completed or were terminated, 435 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
470 of 1,649 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genzyme, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Genzyme, a Sanofi Company is the lead sponsor of 308 studies on the registry; 5 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 19 (76%) have results posted.
Sanofi has 5 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
138 of the studies in Parkinson Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06976268Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease | 2027-08 |
| NCT06098612Massachusetts General HospitalPET Imaging Evaluation of [11C]SY08 | 2026-11 |
| NCT06489483University of Texas Southwestern Medical CenterAction Regulation Behavioral | 2026-11 |
| NCT05558189Stanford UniversityVibrotactile Coordinated Reset for the Treatment of Post Surgery Refractory Parkinson's Disease Patients | 2026-11-21 |
| NCT06773962TrueBinding, Inc.A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease | 2026-11-28 |
Add all 138 to your calendar (.ics) → With an account.
Among the 1,649 studies in Parkinson Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objectives:
Secondary Objectives:
Part 1:
Part 2:
Part 1: the total duration was as following:
i) Rest of the world (ROW): up to approximately 50 weeks (8.5 weeks of screening, maximum of 36 weeks of treatment and 6 weeks follow-up).
ii) Japan only: up to approximately 66 weeks (8.5 weeks of screening, maximum of 52 weeks of treatment and 6 weeks follow-up).
Part 2: the total duration was up to approximately 224 weeks that consisted of 8.5 weeks of screening period, 52 weeks of treatment period, 156 weeks of long-term follow-up (LTFU) period and 8 weeks of post-treatment period.
At the end of a 52-week main placebo-controlled treatment period, all participants were evaluated for possibility to transition to receive active treatment for 156 weeks plus 8-week post-treatment observation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part 1: Increasing doses of GZ/SAR402671 were administered once per day. Part 2: A dose of GZ/SAR402671 (determined in Part 1) was administered once per day.
Drug: venglustat GZ/SAR402671
A matching placebo for Parts 1 and 2 was administered once per day.
Drug: Placebo
Pharmaceutical form: capsule Route of administration: oral
Pharmaceutical form: capsule Route of administration: oral
Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and does not necessarily had to have a causal relationship with the treatment. Serious AEs (SAEs) were any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were the AEs that developed or worsened or became serious during the TEAE period (defined as the period from the time of first investigational medicinal product \[IMP\] administration up of 6 weeks after the last administration of the IMP).
Time frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
Part 1: Number of Participants With Abnormal Physical Examination Findings
Physical examination included following observations/measurements: general appearance; heart, skin, respiratory auscultation; head, eyes, ears, nose, and throat, extremities/joints, and abdomen. New onset of abnormal physical examination was defined as a normal physical examination at Baseline and an abnormal physical examination during the treatment-emergent (TE) period (defined as the period from the time of first IMP administration up of 6 weeks after the last administration of the IMP). Abnormalities in physical examination were based on investigator's evaluation.
Time frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
Part 1: Number of Participants With Abnormal Neurological Examination Findings
Neurological examination included at least assessments of the participant's cranial nerves, motor system (including muscle atrophy, tone, and power), mental status, deep tendon reflex, sensation, and cerebellar function. Abnormalities in neurological examination were based on investigator's evaluation.
Time frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematology
Criteria for potentially clinically significant abnormalities (PCSA): Hemoglobin: less than or equal to (\<=) 115 grams per liter (g/L) (Male\[M\]) or \<=95 g/L (Female\[F\]), greater than or equal to (\>=) 185 g/L (M) or \>=165 g/L (F), Decrease from baseline (DFB) \>=20 g/L; Hematocrit: \<=0.37 volume/volume (v/v) (M) or \<=0.32 v/v (F), \>=0.55 v/v (M) or \>=0.5 v/v (F); Red blood cells (RBC): \>=6 Tera/L; Platelets: less than (\<) 100 Giga/L, \>=700 Giga/L; White blood cells (WBC): \<3.0 Giga/L (Non-Black \[NB\]) or \<2.0 Giga/L (Black \[B\]), \>=16.0 Giga/L; Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); Lymphocytes: \<lower limit of normal (LLN), greater than (\>) 4.0 Giga/L; Monocytes: \<LLN, \>0.7 Giga/L; Basophils: \>0.1 Giga/L; Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L).
Time frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters
Criteria for PCSA: Alanine Aminotransferase (ALT): \>3 ULN, \>5 ULN; Aspartate aminotransferase (AST): \>3 ULN; Alkaline phosphatase: \>1.5 ULN; Total Bilirubin: \>1.5 ULN; ALT and Bilirubin: \>3 ULN and \>2 ULN; Direct Bilirubin and Bilirubin: \>35% and \>1.5 ULN.
Time frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Parameters
Criteria for PCSA: Creatinine: \>=150 micromoles per liter (mcmol/L) (adults), \>=30% change from baseline, \>=100% change from baseline; Blood urea nitrogen: \>=17 millimoles (mmol)/L.
Time frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Metabolic Parameters
Criteria for PCSA: Glucose: \<=3.9 mmol/L and \<LLN; \>=11.1 mmol/L (unfasted \[unfas\]) or \>=7 mmol/L (fasted \[fas\]); Albumin: \<=25 g/L.
Time frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes Parameters
Criteria for PCSA: Sodium: \<=129 mmol/L, \>=160 mmol/L; Potassium: \<3 mmol/L, \>=5.5 mmol/L and Chloride: \<80 mmol/L, \>115 mmol/L.
Time frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
Part 1: Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities
Criteria for PCSA: Systolic blood pressure (SBP) supine: \<=95 millimeters of mercury (mmHg) and DFB \>=20 mmHg; \>=160 mmHg and increase from baseline (IFB) \>=20 mmHg; Diastolic blood pressure (DBP) supine: \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB \>=10 mmHg; SBP (Orthostatic): \<=-20 mmHg; DBP (Orthostatic): \<=-10 mmHg; Heart rate (HR) supine: \<=50 beats per minute (bpm) and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm; Weight: \>=5% DFB; \>=5% IFB.
Time frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
Part 1: Number of Participants With Potentially Clinically Significant Ophthalmological Abnormalities
Clinically significant observations in left eye, right eye and any eye (any eye among left and right) were assessed by the investigator based on methods like visual acuity, slit lamp examination, examination of the cornea, lens, and retina. Any abnormal clinically significant ophthalmological examination finding (which was present at screening or not) on any eye during the treatment-emergent period corresponded to cornea verticillata, cataract and abnormal overall evaluation
Time frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
Part 1: Number of Participants With Potentially Clinically Significant Electrocardiogram Abnormalities
Criteria for PCSA: HR: \<50 bpm; \<50 bpm and DFB \>=20 bpm, \<40 bpm; \>90 bpm, \<90 bpm and IFB \>=20 bpm, \>100 bpm; PR Interval: \>200 milliseconds (msec), \>200 msec and IFB \>=25%, \>220 msec; QRS Interval: \>110 msec, \>110 msec and IFB \>=25%, \>120 msec; QT Interval: \>500 msec; QTc Bazett (QTcB) interval: \>450 msec, \>480 msec, IFB \>30 and \<=60 msec, IFB \>60 msec; QTc Fridericia (QTc F): \>450 msec, \>480 msec, IFB \>30 and \<=60 msec, IFB \>60 msec.
Time frame: From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., up to 42 weeks for ROW and up to 58 weeks for Japanese participants)
Part 2: Change From Baseline to Week 52 in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II+III Total Score
MDS-UPDRS is a multimodal scale consisting of 4 parts. Part II assessed motor experiences of daily living (total score range: 0 to 52). It contained 13 questions completed by the participant. Part III assessed the motor signs of PD and was administered by the rater (total score range: 0 to 132). Part III contained 33 scores based on 18 items. In both parts, higher score indicated more severe symptoms. For each question in both parts, numeric score was assigned between 0 to 4, where 0=Normal, 1=Slight, 2=Mild, 3=Moderate, 4=Severe. MDS-UPDRS Total Part II and III score = sum of Part II and III scores with score ranged from 0 (no symptom) to 184 (severe symptoms), where higher scores reflected more severe symptoms of PD. Data for this OM was not planned to be collected and analyzed for Part 1, Part 2: DB period re-randomized participants and Part 2 LTFU period, as pre-specified in protocol.
Time frame: Baseline to Week 52
Part 2: Change From Baseline to Week 52 in Parkinson's Disease Cognitive Rating Scale (PD-CRS) Total Score
The PD-CRS detects early cognitive impairment in Parkinson's disease. It is composed of 2 scales, the fronto-subcortical scale (items: sustained attention, working memory, alternating and action verbal fluency, clock drawing, immediate, and delayed free recall verbal memory) and the posterior-cortical scale (items: confrontation naming and clock copying). The total score of the fronto-subcortical scale (sum of all items) ranged from 0 (worst) to 104 (maximum score indicates better) and the total score of the posterior-cortical scale (sum of all items) ranged from 0 (worst) to 30 (maximum score indicates better). The PD-CRS Total score = the sum of PD-CRS fronto-subcortical score and the PD-CRS posterior-cortical score, which ranged from 0 to 134, where higher score = less impairment.
Time frame: Baseline to Week 52
Part 2: Change From Baseline to Week 52 in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I+ II+III Score
MDS-UPDRS is a multimodal scale consisting of 4 parts. Part I assessed non-motor experiences of daily living and has 2 components (total score range: 0 to 52): Part IA contained 6 questions and was assessed by the examiner (total score range: 0 to 24). Part IB contained 7 questions on non-motor experiences of daily living which was completed by the participant (total score range: 0 to 28). Part II (13 questions completed by the participant) assessed motor experiences of daily living (total score range: 0 to 52). Part III assessed motor signs of PD and was administered by the rater (total score range: 0 to 132). Part III contained 33 scores based on 18 items. In all parts, higher score indicated more symptoms. For each question, numeric score was assigned between 0 to 4, where 0=Normal, 1=Slight, 2=Mild, 3=Moderate, 4=Severe. MDS-UPDRS total score = sum of Parts I, II, and III (Range: 0 to 236). Higher score = more severe symptoms of PD.
Time frame: Baseline to Week 52
Part 2: Change From Baseline to Week 52 in Hoehn and Yahr (H and Y) Score
H and Y scale measured how Parkinson's symptoms progress and the level of disability. Scale allocated stage scores were from 0 to 5 to indicate relative level of disability as: Stage 0: no symptoms; Stage 1: symptoms on one side of the body only; Stage 2: symptoms on both sides of the body, without impairment of balance; Stage 3: Mild to moderate bilateral disease; some postural instability; physically independent; Stage 4: Severe disability; still able to walk or stand unassisted and Stage 5: Wheelchair bound or bedridden unless aided, where higher stage score described an increased severity of disease.
Time frame: Baseline to Week 52
Study was conducted at 52 sites in 16 countries. A total of 273 participants were enrolled from 15-Dec-2016 to 18-Dec-2019. Study consisted of 2 Parts: Part 1 (dose escalation period) \& Part 2 (double-blind \[DB\] treatment period + long-term follow-up \[LTFU\]) period.
| Milestone | Part 1: Placebo (ROW) | Part 1: Venglustat 4 mg (ROW) | Part 1: Venglustat 8 mg (ROW) | Part 1: Venglustat 15 mg (ROW) | Part 1: Placebo (Japan Only) | Part 1: Venglustat 4 mg (Japan Only) | Part 1: Venglustat 8 mg (Japan Only) | Part 1: Venglustat 15 mg (Japan Only) | Part 2, DB Period: Placebo | Part 2, DB Period: Venglustat 15 mg | Part 2, DB Period: Placebo (Re-randomized From Part 1) | Part 2, DB Period: Venglustat 15 mg (Re-randomized From Part 1) | Part 2, LTFU Period: Placebo Then Venglustat 15 mg | Part 2, LTFU Period: Venglustat 15 mg | Part 2, LTFU: Placebo Then Veng 15 mg (Re-randomized From Part 1) | Part 2, LTFU: Venglustat 15 mg (Re-randomized From Part 1) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 4 | 5 | 4 | 3 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Treated | 4 | 4 | 5 | 4 | 3 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 4 | 3 | 5 | 3 | 3 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Placebo (ROW) | Part 1: Venglustat 4 mg (ROW) | Part 1: Venglustat 8 mg (ROW) | Part 1: Venglustat 15 mg (ROW) | Part 1: Placebo (Japan Only) | Part 1: Venglustat 4 mg (Japan Only) | Part 1: Venglustat 8 mg (Japan Only) | Part 1: Venglustat 15 mg (Japan Only) | Part 2, DB Period: Placebo | Part 2, DB Period: Venglustat 15 mg | Part 2, DB Period: Placebo (Re-randomized From Part 1) | Part 2, DB Period: Venglustat 15 mg (Re-randomized From Part 1) | Part 2, LTFU Period: Placebo Then Venglustat 15 mg | Part 2, LTFU Period: Venglustat 15 mg | Part 2, LTFU: Placebo Then Veng 15 mg (Re-randomized From Part 1) | Part 2, LTFU: Venglustat 15 mg (Re-randomized From Part 1) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 111 | 110 | 10 | 13 | 0 | 0 | 0 | 0 |
| Treated | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 111 | 110 | 10 | 13 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 99 | 85 | 10 | 13 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 25 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 15 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 10 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Placebo (ROW) | Part 1: Venglustat 4 mg (ROW) | Part 1: Venglustat 8 mg (ROW) | Part 1: Venglustat 15 mg (ROW) | Part 1: Placebo (Japan Only) | Part 1: Venglustat 4 mg (Japan Only) | Part 1: Venglustat 8 mg (Japan Only) | Part 1: Venglustat 15 mg (Japan Only) | Part 2, DB Period: Placebo | Part 2, DB Period: Venglustat 15 mg | Part 2, DB Period: Placebo (Re-randomized From Part 1) | Part 2, DB Period: Venglustat 15 mg (Re-randomized From Part 1) | Part 2, LTFU Period: Placebo Then Venglustat 15 mg | Part 2, LTFU Period: Venglustat 15 mg | Part 2, LTFU: Placebo Then Veng 15 mg (Re-randomized From Part 1) | Part 2, LTFU: Venglustat 15 mg (Re-randomized From Part 1) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 99 | 85 | 10 | 11 |
| Treated | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 87 | 75 | 10 | 11 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 99 | 85 | 10 | 11 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 4 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 4 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Poor compliance to protocol | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 67 | 64 | 7 | 8 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 8 | 3 | 2 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and does not necessarily had to have a causal relationship with the treatment. Serious AEs (SAEs) were any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were the AEs that developed or worsened or became serious during the TEAE period (defined as the period from the time of first investigational medicinal product \[IMP\] administration up of 6 weeks after the last administration of the IMP).
| Participants | Part 1: Placebo (ROW) | Part 1: Venglustat 4 mg (ROW) | Part 1: Venglustat 8 mg (ROW) | Part 1: Venglustat 15 mg (ROW) | Part 1: Placebo (Japan Only) | Part 1: Venglustat 4 mg (Japan Only) | Part 1: Venglustat 8 mg (Japan Only) | Part 1: Venglustat 15 mg (Japan Only) |
|---|---|---|---|---|---|---|---|---|
| Any TEAE | 4 | 4 | 4 | 4 | 2 | 3 | 3 | 2 |
| Any TESAE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Physical examination included following observations/measurements: general appearance; heart, skin, respiratory auscultation; head, eyes, ears, nose, and throat, extremities/joints, and abdomen. New onset of abnormal physical examination was defined as a normal physical examination at Baseline and an abnormal physical examination during the treatment-emergent (TE) period (defined as the period from the time of first IMP administration up of 6 weeks after the last administration of the IMP). Abnormalities in physical examination were based on investigator's evaluation.
| Participants | Part 1: Placebo (ROW) | Part 1: Venglustat 4 mg (ROW) | Part 1: Venglustat 8 mg (ROW) | Part 1: Venglustat 15 mg (ROW) | Part 1: Placebo (Japan Only) | Part 1: Venglustat 4 mg (Japan Only) | Part 1: Venglustat 8 mg (Japan Only) | Part 1: Venglustat 15 mg (Japan Only) |
|---|---|---|---|---|---|---|---|---|
| Part 1: Number of Participants With Abnormal Physical Examination Findings | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 |
Neurological examination included at least assessments of the participant's cranial nerves, motor system (including muscle atrophy, tone, and power), mental status, deep tendon reflex, sensation, and cerebellar function. Abnormalities in neurological examination were based on investigator's evaluation.
| Participants | Part 1: Placebo (ROW) | Part 1: Venglustat 4 mg (ROW) | Part 1: Venglustat 8 mg (ROW) | Part 1: Venglustat 15 mg (ROW) | Part 1: Placebo (Japan Only) | Part 1: Venglustat 4 mg (Japan Only) | Part 1: Venglustat 8 mg (Japan Only) | Part 1: Venglustat 15 mg (Japan Only) |
|---|---|---|---|---|---|---|---|---|
| Abnormal cranial nerve examination | 1 | 1 | 1 | 2 | 1 | 3 | 3 | 2 |
| Abnormal motor examination | 3 | 4 | 4 | 3 | 3 | 3 | 3 | 3 |
| Abnormal strength examination | 1 | 4 | 3 | 3 | 1 | 2 | 2 | 1 |
| Abnormal reflex examination | 0 | 1 | 1 | 1 | 0 | 2 | 2 | 0 |
| Abnormal sensory examination | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 0 |
| Abnormal coordination examination | 2 | 1 | 1 | 3 | 1 | 0 | 1 | 2 |
| Abnormal gait and coordination | 3 | 4 | 4 | 2 | 3 | 2 | 2 | 2 |
Criteria for potentially clinically significant abnormalities (PCSA): Hemoglobin: less than or equal to (\<=) 115 grams per liter (g/L) (Male\[M\]) or \<=95 g/L (Female\[F\]), greater than or equal to (\>=) 185 g/L (M) or \>=165 g/L (F), Decrease from baseline (DFB) \>=20 g/L; Hematocrit: \<=0.37 volume/volume (v/v) (M) or \<=0.32 v/v (F), \>=0.55 v/v (M) or \>=0.5 v/v (F); Red blood cells (RBC): \>=6 Tera/L; Platelets: less than (\<) 100 Giga/L, \>=700 Giga/L; White blood cells (WBC): \<3.0 Giga/L (Non-Black \[NB\]) or \<2.0 Giga/L (Black \[B\]), \>=16.0 Giga/L; Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); Lymphocytes: \<lower limit of normal (LLN), greater than (\>) 4.0 Giga/L; Monocytes: \<LLN, \>0.7 Giga/L; Basophils: \>0.1 Giga/L; Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L).
| Participants | Part 1: Placebo (ROW) | Part 1: Venglustat 4 mg (ROW) | Part 1: Venglustat 8 mg (ROW) | Part 1: Venglustat 15 mg (ROW) | Part 1: Placebo (Japan Only) | Part 1: Venglustat 4 mg (Japan Only) | Part 1: Venglustat 8 mg (Japan Only) | Part 1: Venglustat 15 mg (Japan Only) |
|---|---|---|---|---|---|---|---|---|
| Hemoglobin <= 115 g/L (M); ≤ 95 g/L (F) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin >=185 g/L (M) or >=165 g/L (F) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin DFB >=20 g/L | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
| Hematocrit: <=0.37 v/v (M) or <=0.32 v/v (F) | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 |
| Hematocrit: >=0.55 v/v (M); >=0.5 v/v (F) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| RBC: >=6 Tera/L | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets: <100 Giga/L | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Platelets: >=700 Giga/L | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| WBC: <3.0 Giga/L (NB) or <2.0 Giga/L (B) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| WBC: >=16.0 Giga/L | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils <1.5 Giga/L (NB) or <1.0 Giga/L (B) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes: <LLN | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Lymphocytes: >4.0 Giga/L | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Monocytes: <LLN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Monocytes: >0.7 Giga/L | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Basophils: >0.1 Giga/L | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Eosinophils >0.5 Giga/L or >ULN (ULN >=0.5 Giga/L) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Criteria for PCSA: Alanine Aminotransferase (ALT): \>3 ULN, \>5 ULN; Aspartate aminotransferase (AST): \>3 ULN; Alkaline phosphatase: \>1.5 ULN; Total Bilirubin: \>1.5 ULN; ALT and Bilirubin: \>3 ULN and \>2 ULN; Direct Bilirubin and Bilirubin: \>35% and \>1.5 ULN.
| Participants | Part 1: Placebo (ROW) | Part 1: Venglustat 4 mg (ROW) | Part 1: Venglustat 8 mg (ROW) | Part 1: Venglustat 15 mg (ROW) | Part 1: Placebo (Japan Only) | Part 1: Venglustat 4 mg (Japan Only) | Part 1: Venglustat 8 mg (Japan Only) | Part 1: Venglustat 15 mg (Japan Only) |
|---|---|---|---|---|---|---|---|---|
| ALT >3 ULN | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| ALT >5 ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST >3 ULN | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| AST >5 ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alkaline Phosphatase >1.5 ULN | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Total Bilirubin > 1.5 ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT and Bilirubin: >3 ULN and >2 ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Direct Bilirubin and Bilirubin: >35% and >1.5 ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Criteria for PCSA: Creatinine: \>=150 micromoles per liter (mcmol/L) (adults), \>=30% change from baseline, \>=100% change from baseline; Blood urea nitrogen: \>=17 millimoles (mmol)/L.
| Participants | Part 1: Placebo (ROW) | Part 1: Venglustat 4 mg (ROW) | Part 1: Venglustat 8 mg (ROW) | Part 1: Venglustat 15 mg (ROW) | Part 1: Placebo (Japan Only) | Part 1: Venglustat 4 mg (Japan Only) | Part 1: Venglustat 8 mg (Japan Only) | Part 1: Venglustat 15 mg (Japan Only) |
|---|---|---|---|---|---|---|---|---|
| Creatinine >=150 mcmol/L (Adults) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine >=30% change from baseline | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Creatinine >=100% change from baseline | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Urea Nitrogen >=17 mmol/L | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Criteria for PCSA: Glucose: \<=3.9 mmol/L and \<LLN; \>=11.1 mmol/L (unfasted \[unfas\]) or \>=7 mmol/L (fasted \[fas\]); Albumin: \<=25 g/L.
| Participants | Part 1: Placebo (ROW) | Part 1: Venglustat 4 mg (ROW) | Part 1: Venglustat 8 mg (ROW) | Part 1: Venglustat 15 mg (ROW) | Part 1: Placebo (Japan Only) | Part 1: Venglustat 4 mg (Japan Only) | Part 1: Venglustat 8 mg (Japan Only) | Part 1: Venglustat 15 mg (Japan Only) |
|---|---|---|---|---|---|---|---|---|
| Glucose <=3.9 mmol/L and <LLN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Glucose >=11.1 mmol/L (unfas) or >=7 mmol/L (fas) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Albumin <=25 g/L | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Criteria for PCSA: Sodium: \<=129 mmol/L, \>=160 mmol/L; Potassium: \<3 mmol/L, \>=5.5 mmol/L and Chloride: \<80 mmol/L, \>115 mmol/L.
| Participants | Part 1: Placebo (ROW) | Part 1: Venglustat 4 mg (ROW) | Part 1: Venglustat 8 mg (ROW) | Part 1: Venglustat 15 mg (ROW) | Part 1: Placebo (Japan Only) | Part 1: Venglustat 4 mg (Japan Only) | Part 1: Venglustat 8 mg (Japan Only) | Part 1: Venglustat 15 mg (Japan Only) |
|---|---|---|---|---|---|---|---|---|
| Sodium <=129 mmol/L | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sodium >=160 mmol/L | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium <3 mmol/L | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium >=5.5 mmol/L | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chloride <80 mmol/L | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chloride >115 mmol/L | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Criteria for PCSA: Systolic blood pressure (SBP) supine: \<=95 millimeters of mercury (mmHg) and DFB \>=20 mmHg; \>=160 mmHg and increase from baseline (IFB) \>=20 mmHg; Diastolic blood pressure (DBP) supine: \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB \>=10 mmHg; SBP (Orthostatic): \<=-20 mmHg; DBP (Orthostatic): \<=-10 mmHg; Heart rate (HR) supine: \<=50 beats per minute (bpm) and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm; Weight: \>=5% DFB; \>=5% IFB.
| Participants | Part 1: Placebo (ROW) | Part 1: Venglustat 4 mg (ROW) | Part 1: Venglustat 8 mg (ROW) | Part 1: Venglustat 15 mg (ROW) | Part 1: Placebo (Japan Only) | Part 1: Venglustat 4 mg (Japan Only) | Part 1: Venglustat 8 mg (Japan Only) | Part 1: Venglustat 15 mg (Japan Only) |
|---|---|---|---|---|---|---|---|---|
| SBP (supine) <=95 mmHg and DFB >=20 mmHg | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 |
| SBP (supine) >=160 mmHg and IFB >=20 mmHg | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| DBP (supine) <=45 mmHg and DFB >=10 mmHg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DBP (supine) >=110 mmHg and IFB >=10 mmHg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SBP (Orthostatic): <=-20 mmHg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DBP (Orthostatic): <=-10 mmHg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HR (supine) <=50 bpm and DFB >= 20 bpm | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HR (supine) >=120 bpm and IFB >=20 bpm | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Weight >=5% DFB | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Weight >=5% IFB | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Clinically significant observations in left eye, right eye and any eye (any eye among left and right) were assessed by the investigator based on methods like visual acuity, slit lamp examination, examination of the cornea, lens, and retina. Any abnormal clinically significant ophthalmological examination finding (which was present at screening or not) on any eye during the treatment-emergent period corresponded to cornea verticillata, cataract and abnormal overall evaluation
| Participants | Part 1: Placebo (ROW) | Part 1: Venglustat 4 mg (ROW) | Part 1: Venglustat 8 mg (ROW) | Part 1: Venglustat 15 mg (ROW) | Part 1: Placebo (Japan Only) | Part 1: Venglustat 4 mg (Japan Only) | Part 1: Venglustat 8 mg (Japan Only) | Part 1: Venglustat 15 mg (Japan Only) |
|---|---|---|---|---|---|---|---|---|
| Any eye | 3 | 3 | 4 | 2 | 2 | 3 | 3 | 0 |
| Right eye | 3 | 3 | 4 | 2 | 2 | 2 | 3 | 0 |
| Left eye | 3 | 3 | 4 | 2 | 2 | 3 | 3 | 0 |
Criteria for PCSA: HR: \<50 bpm; \<50 bpm and DFB \>=20 bpm, \<40 bpm; \>90 bpm, \<90 bpm and IFB \>=20 bpm, \>100 bpm; PR Interval: \>200 milliseconds (msec), \>200 msec and IFB \>=25%, \>220 msec; QRS Interval: \>110 msec, \>110 msec and IFB \>=25%, \>120 msec; QT Interval: \>500 msec; QTc Bazett (QTcB) interval: \>450 msec, \>480 msec, IFB \>30 and \<=60 msec, IFB \>60 msec; QTc Fridericia (QTc F): \>450 msec, \>480 msec, IFB \>30 and \<=60 msec, IFB \>60 msec.
| Participants | Part 1: Placebo (ROW) | Part 1: Venglustat 4 mg (ROW) | Part 1: Venglustat 8 mg (ROW) | Part 1: Venglustat 15 mg (ROW) | Part 1: Placebo (Japan Only) | Part 1: Venglustat 4 mg (Japan Only) | Part 1: Venglustat 8 mg (Japan Only) | Part 1: Venglustat 15 mg (Japan Only) |
|---|---|---|---|---|---|---|---|---|
| HR: <50 bpm | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 |
| HR: <50 bpm and DFB >=20 bpm | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HR: <40 bpm | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HR: >90 bpm | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| HR: >90 bpm and IFB >=20 bpm | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HR: >100 bpm | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PR Interval: >200 msec | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| PR Interval: >200 msec and IFB >=25% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PR Interval: >220 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QRS Interval: >110 msec | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| QRS Interval: >110 msec and IFB >=25% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QRS Interval: >120 msec | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| QT Interval: >500 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcB interval: >450 msec | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| QTcB interval: >480 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcB interval: IFB >30 and <=60 msec | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| QTcB interval: IFB >60 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QTc F: >450 msec | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| QTc F: >480 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QTc F: IFB >30 and <=60 msec | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| QTc F: IFB >60 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MDS-UPDRS is a multimodal scale consisting of 4 parts. Part II assessed motor experiences of daily living (total score range: 0 to 52). It contained 13 questions completed by the participant. Part III assessed the motor signs of PD and was administered by the rater (total score range: 0 to 132). Part III contained 33 scores based on 18 items. In both parts, higher score indicated more severe symptoms. For each question in both parts, numeric score was assigned between 0 to 4, where 0=Normal, 1=Slight, 2=Mild, 3=Moderate, 4=Severe. MDS-UPDRS Total Part II and III score = sum of Part II and III scores with score ranged from 0 (no symptom) to 184 (severe symptoms), where higher scores reflected more severe symptoms of PD. Data for this OM was not planned to be collected and analyzed for Part 1, Part 2: DB period re-randomized participants and Part 2 LTFU period, as pre-specified in protocol.
| units on a scale | Part 2, DB Period: Placebo | Part 2, DB Period: Venglustat 15 mg |
|---|---|---|
| Part 2: Change From Baseline to Week 52 in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II+III Total Score | 4.71 ± 1.27 | 7.29 ± 1.36 |
The PD-CRS detects early cognitive impairment in Parkinson's disease. It is composed of 2 scales, the fronto-subcortical scale (items: sustained attention, working memory, alternating and action verbal fluency, clock drawing, immediate, and delayed free recall verbal memory) and the posterior-cortical scale (items: confrontation naming and clock copying). The total score of the fronto-subcortical scale (sum of all items) ranged from 0 (worst) to 104 (maximum score indicates better) and the total score of the posterior-cortical scale (sum of all items) ranged from 0 (worst) to 30 (maximum score indicates better). The PD-CRS Total score = the sum of PD-CRS fronto-subcortical score and the PD-CRS posterior-cortical score, which ranged from 0 to 134, where higher score = less impairment.
| units on a scale | Part 2, DB Period: Placebo | Part 2, DB Period: Venglustat 15 mg |
|---|---|---|
| Part 2: Change From Baseline to Week 52 in Parkinson's Disease Cognitive Rating Scale (PD-CRS) Total Score | 0.32 ± 1.27 | -0.65 ± 1.35 |
MDS-UPDRS is a multimodal scale consisting of 4 parts. Part I assessed non-motor experiences of daily living and has 2 components (total score range: 0 to 52): Part IA contained 6 questions and was assessed by the examiner (total score range: 0 to 24). Part IB contained 7 questions on non-motor experiences of daily living which was completed by the participant (total score range: 0 to 28). Part II (13 questions completed by the participant) assessed motor experiences of daily living (total score range: 0 to 52). Part III assessed motor signs of PD and was administered by the rater (total score range: 0 to 132). Part III contained 33 scores based on 18 items. In all parts, higher score indicated more symptoms. For each question, numeric score was assigned between 0 to 4, where 0=Normal, 1=Slight, 2=Mild, 3=Moderate, 4=Severe. MDS-UPDRS total score = sum of Parts I, II, and III (Range: 0 to 236). Higher score = more severe symptoms of PD.
| units on a scale | Part 2, DB Period: Placebo | Part 2, DB Period: Venglustat 15 mg |
|---|---|---|
| Part 2: Change From Baseline to Week 52 in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I+ II+III Score | 5.87 ± 1.45 | 9.99 ± 1.55 |
H and Y scale measured how Parkinson's symptoms progress and the level of disability. Scale allocated stage scores were from 0 to 5 to indicate relative level of disability as: Stage 0: no symptoms; Stage 1: symptoms on one side of the body only; Stage 2: symptoms on both sides of the body, without impairment of balance; Stage 3: Mild to moderate bilateral disease; some postural instability; physically independent; Stage 4: Severe disability; still able to walk or stand unassisted and Stage 5: Wheelchair bound or bedridden unless aided, where higher stage score described an increased severity of disease.
| units on a scale | Part 2, DB Period: Placebo | Part 2, DB Period: Venglustat 15 mg |
|---|---|---|
| Part 2: Change From Baseline to Week 52 in Hoehn and Yahr (H and Y) Score | 0.18 ± 0.05 | 0.20 ± 0.06 |
Collected over From the first IMP administration up to 6 weeks after the last administration of the IMP (i.e., in Part 1: up to 42 weeks for ROW, up to 58 weeks for Japanese participants; in Part 2 DB period: up to 60 weeks; in Part 2 LTFU period: up to 164 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Placebo (ROW) | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Part 1: Venglustat 4 mg (ROW) | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Part 1: Venglustat 8 mg (ROW) | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| Part 1: Venglustat 15 mg (ROW) | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Part 1: Placebo (Japan Only) | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Part 1: Venglustat 4 mg (Japan Only) | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Part 1: Venglustat 8 mg (Japan Only) | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Part 1: Venglustat 15 mg (Japan Only) | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Part 2, DB Period: Placebo | 0/111 (0%) | 12/111 (10.8%) | 87/111 (78.4%) |
| Part 2, DB Period: Venglustat 15 mg | 1/110 (0.9%) | 12/110 (10.9%) | 95/110 (86.4%) |
| Part 2, DB Period: Placebo (Re-randomized From Part 1) | 0/10 (0%) | 0/10 (0%) | 8/10 (80%) |
| Part 2, DB Period: Venglustat 15 mg (Re-randomized From Part 1) | 0/13 (0%) | 3/13 (23.1%) | 11/13 (84.6%) |
| Part 2, LTFU Period: Placebo Then Venglustat 15 mg | 1/87 (1.1%) | 15/87 (17.2%) | 53/87 (60.9%) |
| Part 2, LTFU Period: Venglustat 15 mg | 0/75 (0%) | 9/75 (12%) | 39/75 (52%) |
| Part 2, LTFU: Placebo Then Veng 15 mg (Re-randomized From Part 1) | 0/10 (0%) | 3/10 (30%) | 7/10 (70%) |
| Part 2, LTFU: Venglustat 15 mg (Re-randomized From Part 1) | 0/11 (0%) | 1/11 (9.1%) | 8/11 (72.7%) |
| Event | Part 1: Placebo (ROW) | Part 1: Venglustat 4 mg (ROW) | Part 1: Venglustat 8 mg (ROW) | Part 1: Venglustat 15 mg (ROW) | Part 1: Placebo (Japan Only) | Part 1: Venglustat 4 mg (Japan Only) | Part 1: Venglustat 8 mg (Japan Only) | Part 1: Venglustat 15 mg (Japan Only) | Part 2, DB Period: Placebo | Part 2, DB Period: Venglustat 15 mg | Part 2, DB Period: Placebo (Re-randomized From Part 1) | Part 2, DB Period: Venglustat 15 mg (Re-randomized From Part 1) | Part 2, LTFU Period: Placebo Then Venglustat 15 mg | Part 2, LTFU Period: Venglustat 15 mg | Part 2, LTFU: Placebo Then Veng 15 mg (Re-randomized From Part 1) | Part 2, LTFU: Venglustat 15 mg (Re-randomized From Part 1) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Covid-19Infections and infestations | 0/4 | 0/4 | 0/5 | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/111 | 0/110 | 0/10 | 0/13 | 0/87 | 0/75 | 1/10 | 0/11 |
| Cognitive DisorderNervous system disorders | 0/4 | 0/4 | 0/5 | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/111 | 1/110 | 0/10 | 0/13 | 0/87 | 0/75 | 1/10 | 0/11 |
| Confusional StatePsychiatric disorders | 0/4 | 0/4 | 0/5 | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/111 | 0/110 | 0/10 | 0/13 | 0/87 | 1/75 | 1/10 | 0/11 |
| Intentional OverdoseInjury, poisoning and procedural complications | 0/4 | 0/4 | 0/5 | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/111 | 0/110 | 0/10 | 0/13 | 0/87 | 0/75 | 0/10 | 1/11 |
| Suicide AttemptPsychiatric disorders | 0/4 | 0/4 | 0/5 | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/111 | 0/110 | 0/10 | 0/13 | 0/87 | 0/75 | 0/10 | 1/11 |
| Inguinal HerniaGastrointestinal disorders | 0/4 | 0/4 | 0/5 | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/111 | 0/110 | 0/10 | 1/13 | 0/87 | 0/75 | 0/10 | 0/11 |
| PneumoniaInfections and infestations | 0/4 | 0/4 | 0/5 | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/111 | 0/110 | 0/10 | 1/13 | 0/87 | 0/75 | 0/10 | 0/11 |
| SepsisInfections and infestations | 0/4 | 0/4 | 0/5 | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/111 | 0/110 | 0/10 | 1/13 | 0/87 | 0/75 | 0/10 | 0/11 |
| Urinary Tract InfectionInfections and infestations | 0/4 | 0/4 | 0/5 | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/111 | 0/110 | 0/10 | 1/13 | 1/87 | 0/75 | 0/10 | 0/11 |
| Transient Ischaemic AttackNervous system disorders | 0/4 | 0/4 | 0/5 | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/111 | 1/110 | 0/10 | 1/13 | 0/87 | 0/75 | 0/10 | 0/11 |
| Event | Part 1: Placebo (ROW) | Part 1: Venglustat 4 mg (ROW) | Part 1: Venglustat 8 mg (ROW) | Part 1: Venglustat 15 mg (ROW) | Part 1: Placebo (Japan Only) | Part 1: Venglustat 4 mg (Japan Only) | Part 1: Venglustat 8 mg (Japan Only) | Part 1: Venglustat 15 mg (Japan Only) | Part 2, DB Period: Placebo | Part 2, DB Period: Venglustat 15 mg | Part 2, DB Period: Placebo (Re-randomized From Part 1) | Part 2, DB Period: Venglustat 15 mg (Re-randomized From Part 1) | Part 2, LTFU Period: Placebo Then Venglustat 15 mg | Part 2, LTFU Period: Venglustat 15 mg | Part 2, LTFU: Placebo Then Veng 15 mg (Re-randomized From Part 1) | Part 2, LTFU: Venglustat 15 mg (Re-randomized From Part 1) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/4 | 1/4 | 0/5 | 0/4 | 0/3 | 2/3 | 0/3 | 0/3 | 8/111 | 23/110 | 0/10 | 1/13 | 5/87 | 0/75 | 0/10 | 1/11 |
| VomitingGastrointestinal disorders | 0/4 | 0/4 | 0/5 | 0/4 | 0/3 | 2/3 | 0/3 | 0/3 | 3/111 | 9/110 | 0/10 | 0/13 | 4/87 | 0/75 | 0/10 | 0/11 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/4 | 2/4 | 0/5 | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 7/111 | 5/110 | 1/10 | 1/13 | 0/87 | 4/75 | 0/10 | 0/11 |
| HeadacheNervous system disorders | 2/4 | 0/4 | 1/5 | 0/4 | 0/3 | 1/3 | 0/3 | 0/3 | 15/111 | 22/110 | 0/10 | 3/13 | 2/87 | 3/75 | 0/10 | 0/11 |
| AnxietyPsychiatric disorders | 0/4 | 0/4 | 0/5 | 2/4 | 0/3 | 0/3 | 0/3 | 0/3 | 6/111 | 5/110 | 0/10 | 2/13 | 7/87 | 2/75 | 1/10 | 0/11 |
| DiarrhoeaGastrointestinal disorders | 0/4 | 0/4 | 2/5 | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 4/111 | 5/110 | 0/10 | 0/13 | 1/87 | 1/75 | 0/10 | 0/11 |
| Hallucination, VisualPsychiatric disorders | 0/4 | 0/4 | 2/5 | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/111 | 1/110 | 0/10 | 1/13 | 1/87 | 1/75 | 1/10 | 0/11 |
| VertigoEar and labyrinth disorders | 0/4 | 0/4 | 0/5 | 1/4 | 0/3 | 1/3 | 0/3 | 0/3 | 2/111 | 0/110 | 1/10 | 0/13 | 1/87 | 0/75 | 0/10 | 0/11 |
| GlaucomaEye disorders | 0/4 | 0/4 | 0/5 | 0/4 | 0/3 | 0/3 | 1/3 | 0/3 | 0/111 | 1/110 | 0/10 | 0/13 | 0/87 | 1/75 | 0/10 | 0/11 |
| Abdominal DiscomfortGastrointestinal disorders | 0/4 | 0/4 | 0/5 | 0/4 | 0/3 | 1/3 | 0/3 | 0/3 | 0/111 | 0/110 | 0/10 | 0/13 | 0/87 | 0/75 | 0/10 | 0/11 |
Analysis was performed on all randomized unique participants (N=250) only.
| Age, Continuous(years) | Part 1: Placebo (ROW) | Part 1: Venglustat 4 mg (ROW) | Part 1: Venglustat 8 mg (ROW) | Part 1: Venglustat 15 mg (ROW) | Part 1: Placebo (Japan Only) | Part 1: Venglustat 4 mg (Japan Only) | Part 1: Venglustat 8 mg (Japan Only) | Part 1: Venglustat 15 mg (Japan Only) | Part 2, DB Period: Placebo | Part 2, DB Period: Venglustat 15 mg | Total Title |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 53.0 ± 8.8 | 55.0 ± 3.9 | 61.0 ± 6.9 | 63.8 ± 8.7 | 52.0 ± 10.4 | 61.7 ± 5.9 | 56.7 ± 4.0 | 46.7 ± 8.1 | 59.8 ± 8.5 | 58.2 ± 9.8 | 58.7 ± 9.1 |
| Sex: Female, Male(Participants) | Part 1: Placebo (ROW) | Part 1: Venglustat 4 mg (ROW) | Part 1: Venglustat 8 mg (ROW) | Part 1: Venglustat 15 mg (ROW) | Part 1: Placebo (Japan Only) | Part 1: Venglustat 4 mg (Japan Only) | Part 1: Venglustat 8 mg (Japan Only) | Part 1: Venglustat 15 mg (Japan Only) | Part 2, DB Period: Placebo | Part 2, DB Period: Venglustat 15 mg | Total Title |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 1 | 1 | 1 | 0 | 3 | 1 | 1 | 43 | 45 | 97 |
| Male | 3 | 3 | 4 | 3 | 3 | 0 | 2 | 2 | 68 | 65 | 153 |
| Race (NIH/OMB)(Participants) | Part 1: Placebo (ROW) | Part 1: Venglustat 4 mg (ROW) | Part 1: Venglustat 8 mg (ROW) | Part 1: Venglustat 15 mg (ROW) | Part 1: Placebo (Japan Only) | Part 1: Venglustat 4 mg (Japan Only) | Part 1: Venglustat 8 mg (Japan Only) | Part 1: Venglustat 15 mg (Japan Only) | Part 2, DB Period: Placebo | Part 2, DB Period: Venglustat 15 mg | Total Title |
|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 3 | 3 | 3 | 3 | 7 | 10 | 29 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 4 | 4 | 5 | 4 | 0 | 0 | 0 | 0 | 104 | 100 | 221 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Dec 2016 to primary completion in Dec 2020, 48 months.
Results were first posted in Feb 2022, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.